Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: dates

Availability of Preparatory Documents for the Combined General Meeting of May 22, 2026

AG 2026

Published 4 May 2026
Categorized as 2025, 2025, 2026, 2026, Press release

Transgene Provides Business and Financial Update for Q1 2026

Q1 2026

Published 29 April 2026
Categorized as 2025, 2025, 2026, 2026, Press release

First Half 2026 Financial Results

Published 29 April 2026
Categorized as 2026, Financial calendar

Synthetic Genome Shuffling of Poxviruses via Yeast TAR Cloning for Next-Generation Oncolytic Platforms

A. Agaoua et al. International Oncolytic Virus Conference 2026 – Download the Abstract – Download the Poster

Published 26 April 2026
Categorized as -others, 2026, 2026, Publication, publication key en

Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer

TG4050

Published 13 April 2026
Categorized as 2025, 2025, 2026, 2026, Myvac, Press release, TG4050

Transgene to Participate in Upcoming Investor Meetings

Investor meetings

Published 7 April 2026
Categorized as 2025, 2025, 2026, 2026, Press release

Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer

Licence Agreement

Published 2 April 2026
Categorized as 2025, 2026, Press release, TG4050

TG4050, an Individualized Neoantigen Therapeutic Vaccine in Early-Stage Cancer Treatment

K. Bidet-Huang World Vaccine Congress 2026 – Download the Oral Presentation

Published 1 April 2026
Categorized as 2026, Myvac, Publication, publication key en, TG4050

Transgene to Deliver an Oral Presentation on its Individualized Neoantigen Therapeutic Vaccine TG4050 at the World Vaccine Congress

WVC 2026

Published 26 March 2026
Categorized as 2026, Press release

2025 Full-year results and business update

link to webcast

Published 24 March 2026
Categorized as 2025, Myvac, TG4050, Webcast, Webcast

Posts pagination

Newer posts Page 1 … Page 3 … Page 47 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu